A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
© 2022. The Author(s)..
In recent years, tattooing technology has shown promising results toward evaluating vaccines in both animal models and humans. However, this technology has some limitations due to variability of experimental evaluations or operator procedures. The current study evaluated a device (intradermal oscillating needle array injection device: IONAID) capable of microinjecting a controlled dose of any aqueous vaccine into the intradermal space. IONAID-mediated administration of a DNA-based vaccine encoding the glycoprotein (GP) from the Ebola virus resulted in superior T- and B-cell responses with IONAID when compared to single intramuscular (IM) or intradermal (ID) injection in mice. Moreover, humoral immune responses, induced after IONAID vaccination, were significantly higher to those obtained with traditional passive DNA tattooing in guinea pigs and rabbits. This device was well tolerated and safe during HIV vaccine delivery in non-human primates (NHPs), while inducing robust immune responses. In summary, this study shows that the IONAID device improves vaccine performance, which could be beneficial to the animal and human health, and importantly, provide a dose-sparing approach (e.g., monkeypox vaccine).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
NPJ vaccines - 7(2022), 1 vom: 22. Dez., Seite 172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomez, Alejandro M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 23.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-022-00581-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350553696 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350553696 | ||
| 003 | DE-627 | ||
| 005 | 20231226045247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-022-00581-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350553696 | ||
| 035 | |a (NLM)36543794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomez, Alejandro M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a In recent years, tattooing technology has shown promising results toward evaluating vaccines in both animal models and humans. However, this technology has some limitations due to variability of experimental evaluations or operator procedures. The current study evaluated a device (intradermal oscillating needle array injection device: IONAID) capable of microinjecting a controlled dose of any aqueous vaccine into the intradermal space. IONAID-mediated administration of a DNA-based vaccine encoding the glycoprotein (GP) from the Ebola virus resulted in superior T- and B-cell responses with IONAID when compared to single intramuscular (IM) or intradermal (ID) injection in mice. Moreover, humoral immune responses, induced after IONAID vaccination, were significantly higher to those obtained with traditional passive DNA tattooing in guinea pigs and rabbits. This device was well tolerated and safe during HIV vaccine delivery in non-human primates (NHPs), while inducing robust immune responses. In summary, this study shows that the IONAID device improves vaccine performance, which could be beneficial to the animal and human health, and importantly, provide a dose-sparing approach (e.g., monkeypox vaccine) | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Babuadze, George Giorgi |e verfasserin |4 aut | |
| 700 | 1 | |a Plourde-Campagna, Marc-André |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Hiva |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Kozak, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a de La Vega, Marc-Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Xiii, Ara |e verfasserin |4 aut | |
| 700 | 1 | |a Naghibosadat, Maedeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nepveu-Traversy, Marie-Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Ruel, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Kobinger, Gary P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 7(2022), 1 vom: 22. Dez., Seite 172 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:22 |g month:12 |g pages:172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-022-00581-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 22 |c 12 |h 172 | ||